Drug Topics

SEPTEMBER 24, 2024

Check out these featured Drug Topics interviews from September 2024.

281

281

PharmaVoice

SEPTEMBER 24, 2024

Alicia Zhou brings startup bona fides to the nonprofit Cancer Research Institute to promote defragmentation of the cancer research effort.

182

182

Drug Topics

SEPTEMBER 24, 2024

Johnny Garcia, Senior Director of Policy at the Pharmaceutical Care Management Association, discussed the role his company plays in the ongoing issue of rising drug prices.

281

281

STAT

SEPTEMBER 24, 2024

Many disabled people are not included in official U.S. data. This is because there is “ No Box to Check ” to indicate their particular disability on surveys from the U.S. Census Bureau and other federal agencies. The questions used to identify people with disabilities are missing millions. Two question sets are most often used to assess disability in U.S. federal surveys: the American Community Survey Six (ACS-6) or the Washington Group Short Set (WG-SS).

145

145

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Patient Care

Drug Topics

SEPTEMBER 24, 2024

In the US, Ozempic costs more than 9 times what it does in Germany, while Wegovy is more than 4.5 times more expensive than in Denmark.

247

247

Pharmacy Times

SEPTEMBER 24, 2024

Researchers found that PF4/Cxcl4, a key driver of fibrosis, was up regulated on all proteomes.

145

145

Pharmacy Times

SEPTEMBER 24, 2024

Investigators reported that more than half of individuals had great knowledge about protecting themselves from COVID-19.

Vaccines 139

Vaccines 139

STAT

SEPTEMBER 24, 2024

STAT is co-publishing this article by Tradeoffs. Lisa Ann Trainor struggled to stay on top of schoolwork, hold a job or even perform basic tasks like laundry for six exhausting years. Then, in 2018, she finally found a drug that kept her ADHD in check.

143

143

Pharmacy Times

SEPTEMBER 24, 2024

The meeting will focus on the basic, preclinical, and clinical aspects of myeloma, including precursor disease, high-risk disease, immunotherapies, novel biomarkers, and more.

132

132

STAT

SEPTEMBER 24, 2024

WASHINGTON — Senate health committee chair Bernie Sanders said major drug middlemen have agreed not to limit coverage of Novo Nordisk’s Ozempic and Wegovy if the company lowers the prices of the treatments. It’s Sanders’ latest move to pressure Novo to cut the prices of the blockbuster diabetes and obesity therapies. Novo has been blaming pharmacy benefit managers for the high list prices of its drugs, arguing that it needs to be able to pay rebates to the middlemen i

142

142

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

Fierce Healthcare

SEPTEMBER 24, 2024

Pomelo Care, a value-based virtual provider of maternity care, has acquired the Doula Network, now offering virtual and in-person maternity care. | The acquisition expands the company’s reach to more than 15 million covered lives, including more than 1 in 6 Medicaid beneficiaries nationally.

132

132

STAT

SEPTEMBER 24, 2024

Sanofi named a new chief scientific officer this week, part of a series of moves that the drug company has argued will establish it as being more focused on research and development than in the past. In an internal memo obtained by STAT, Sanofi said Monday that it has named Mike Quigley, formerly the CEO of startups Dualitas Therapeutics and Therini Bio and senior vice president of research biology at Gilead, as its chief scientific officer and global head of research.

132

132

Pharmacy Times

SEPTEMBER 24, 2024

Childhood immunization according to schedule can prevent serious illness.

Immunization 130

Immunization Vaccines 130

STAT

SEPTEMBER 24, 2024

This summer, the American Red Cross declared an emergency blood shortage in the U.S. There’s a seasonal pattern to blood donations, which often dip over the summer and during the winter holidays. But experts also say that climate change disrupts the national blood supply, with extreme heat and worsening storms in certain regions keeping people away from blood banks.

131

131

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

FDA

Pharmacy Is Right For Me

SEPTEMBER 24, 2024

Hi Future Pharmacists! My name is Tazche Turner and I am a fourth year PharmD Candidate at the University of North Carolina’s (UNC) Eshelman School of Pharmacy. My passions for science, business and service led me to pursue a career in pharmacy. Throughout pharmacy school, I immersed myself into numerous organizations and leadership positions to really explore all pharmacy has to offer, but the organization I found my pharmacy home in was the Student National Pharmaceutical Association (SNPhA).

Immunization 130

Immunization 130

Fierce Healthcare

SEPTEMBER 24, 2024

HHS OIG released an analysis of recent RPM claims data, flagging evidence of gaps in CMS oversight. Stakeholders say the report is hyperbolic.

129

129

STAT

SEPTEMBER 24, 2024

Amgen on Tuesday reported that a pair of antibody drugs it is developing as treatments for immune-mediated diseases succeeded in late-stage trials, but the therapies did not clearly beat existing competitors on the market. In the Phase 3 trials, dubbed Horizon and Mint, the California company tested therapies for eczema and myasthenia gravis, respectively.

Immunization 128

Immunization 128

Pharmaceutical Technology

SEPTEMBER 24, 2024

Coverage for its long-acting insulin, Levamir, dropped from 90% to about 35% when the company dropped its list price by 65%.

124

124

Advertisement

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

Pharmacy Management Software

STAT

SEPTEMBER 24, 2024

Generate:Biomedicines, a Flagship Pioneering company using artificial intelligence to create new medicines, announced today that it has struck a deal with Novartis to develop an undisclosed number of targets in various disease areas. With milestone payments, the company is eligible to receive over $1 billion, in addition to royalties. Novartis is paying Generate $65 million up front, which includes $15 million for an undisclosed amount of equity in the company.

125

125

Fierce Healthcare

SEPTEMBER 24, 2024

The feds have set new deadlines for compliance with Medicaid renewal requirements given widespread enrollment concerns during the unwinding. | The feds have set new deadlines for compliance with Medicaid renewal requirements given widespread enrollment concerns during the unwinding.

124

124

Pharmacy Times

SEPTEMBER 24, 2024

The FDA assigned a Prescription Drug User Fee Act action date of May 22, 2025.

FDA 123

FDA 123

Fierce Healthcare

SEPTEMBER 24, 2024

Healthcare philanthropies and two major health systems have announced a 30-year, $700 million collaboration to grow value-based specialty and virtual care in Northwest Arkansas. | The collaboration, which also taps Cleveland Clinic expertise and branding, will develop specialty care centers of excellence with a focus on telehealth and value-based, whole person care.

121

121

Pharmacy Times

SEPTEMBER 24, 2024

Compared with chemotherapy, datopotamab deruxtecan (Dato-DXd) did not achieve a statistically significant overall survival (OS) in patients with inoperable or metastatic HR+/HER2-low or negative breast cancer.

Chemotherapy 123

Chemotherapy 123

STAT

SEPTEMBER 24, 2024

Good morning, lots of news today so we’ll get straight into it. The need-to-know this morning Bluebird Bio said it will lay off 25% of its workforce as part of a restructuring plan needed to reduce the company’s cash operating expenses by 20%. Bluebird has struggled to generate revenue from three approved gene therapies, including Lyfgenia for sickle cell disease.

120

120

pharmaphorum

SEPTEMBER 24, 2024

After various twists and turns in the regulator path, Ipsen has secured EU approval for Kayfanda, its treatment for severe itching (pruritus) in patients with the rare liver disease Alagille syndrome (ALGS).Kayfanda (odevixibat) is labeled in the EU to treat cholestatic pruritus – itching caused by impaired bile formation or flow – in children aged six months and over with ALGS, a disease caused by a genetic mutation that leads to liver damage and jaundice.

Labelling 118

Labelling 118

Fierce Pharma

SEPTEMBER 24, 2024

With the launch of Casgevy gaining momentum, Vertex Pharmaceuticals is adding another link to its gene-editing therapy supply chain. | Vertex has inked a long-term supply agreement with Swiss CDMO Lonza to crank out global commercial supply of Casgevy. Under the deal, Lonza will produce Casgevy from its cell therapy manufacturing facilities in Geleen in the Netherlands and, eventually, its plant in Portsmouth, New Hampshire.

115

115

STAT

SEPTEMBER 24, 2024

What was that mosquito thinking as the six needles of its proboscis mouth bit into my mother’s skin? Had it taken a long, unplanned journey in a bag as a tourist traveled north from a tropical Caribbean island? Or was it an old-time New York mosquito that had feasted the night before on the sweaty skin of a feverish traveler from the south? My mother would remain incredulous at her bad luck: Why did this mosquito choose her arm to snack upon?

114

114

Fierce Pharma

SEPTEMBER 24, 2024

After bluebird bio acknowledged troubles keeping its business operational, the gene therapy biotech is launching a restructuring that will reduce the size of its workforce by about 25%. | After bluebird bio acknowledged troubles keeping its business operational, the gene therapy biotech is launching a restructuring that will reduce the size of its workforce by about 25%, or nearly 100 employees.

112

112

The Checkup by Singlecare

SEPTEMBER 24, 2024

You might think you’re a health-conscious person, but how far does your commitment really go? Would you be willing to consume a drink brewed with something that looks and sounds like a high school science fair project to potentially improve your health? If you said yes, then keep reading. Kombucha is the beverage you get when you ferment tea with a SCOBY or a symbiotic culture of bacteria and yeast (in other words, a living, thriving colony of microorganisms…floating around in your tea).

Health and Personal Care Stores 111

Health and Personal Care Stores Labelling Compounding 111

PioneerRx

SEPTEMBER 24, 2024

It's the people who make the job. From both sides of the pharmacy counter, your patients and pharmacy staff set the tone and tempo for your pharmacy operations.

111

111

STAT

SEPTEMBER 24, 2024

Shares of Regeneron fell 5% yesterday after the company’s effort to block Amgen from launching a biosimilar version of its blockbuster eye drug Eylea hit a legal roadblock.  The judge overseeing a patent infringement case denied Regeneron’s request for a temporary injunction that would have barred Amgen from immediately selling its Eylea copy, called Pavblu.

111

111

pharmaphorum

SEPTEMBER 24, 2024

Roche launches 12 in one test for respiratory virus, using its 'revolutionary' TAGS tech, that can be used in regular clinical labs

109

109

STAT

SEPTEMBER 24, 2024

You’re reading the web edition of STAT’s Health Tech newsletter, our guide to how technology is transforming the life sciences. Sign up to get it  delivered in your inbox every Tuesday and Thursday. Texas AG reaches settlement in health AI probe In other legal news, the Texas Attorney General has reached a settlement with a Dallas health AI company that the government charged with making false claims about its products’ accuracy and safety before deploying them at Texas

Hospitals 108

Hospitals 108